The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Immune Response Disease Clinical Trials 40

Drug Discovery World

APRIL 14, 2023

Schreiber’s award lecture will be held on Monday April 17 at 5:30pm ET. Doctors said not to worry.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

NOVEMBER 29, 2020

Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system.

Vaccine 52

Vaccine Clinical Trials Disease Therapies 52

PLOS: DNA Science

MAY 16, 2024

Many of the links below are to some of the 100+ DNA Science posts that I wrote during the pandemic. ” I’ve long thought that SARS-CoV-2, or an immediate viral predecessor, emerged years before 2019 – at least as far back as 2013. But I think about that time often, and the warning that it sounded.

Virus 82

Virus DNA RNA Laboratories 82

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. Cancers 11 , 394 (2019). & Ohi, R.)

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

DECEMBER 27, 2020

Following changes to our leadership team in late 2018 and early 2019, we have sought to transform Lineage into the preeminent allogeneic cell transplant company. Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies.

Therapies 52

Therapies Clinical Trials Production Treatment 52

Codon

JULY 27, 2023

They’ve just finished sequencing the patient’s genome, but they don’t have “DNA sorting” software. billion units of DNA code are transcribed into more than a hundred volumes, each a thousand pages long, in type so small as to be barely legible.” a lower risk of immune responses.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

They’ve just finished sequencing the patient’s genome, but they don’t have “DNA sorting” software. billion units of DNA code are transcribed into more than a hundred volumes, each a thousand pages long, in type so small as to be barely legible.” a lower risk of immune responses.

Therapies 52

Therapies RNA DNA Engineering 52

Drug Discovery World

FEBRUARY 2, 2023

The lead AdAPT candidate, AdAPT-001, in a Phase I/II clinical trial for the treatment of cancer, carries an extra piece of DNA called a transgene that binds to, traps, and neutralises a molecule called transforming growth factor-beta (TGF-b), which tumours hijack to suppress the antitumour immune response. Future Oncol.

Small Molecule 130

Small Molecule Clinical Trials Disease Therapies 130

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

PLOS: DNA Science

OCTOBER 19, 2023

Last week DNA Science covered a setback in a clinical trial of a gene therapy for Duchenne muscular dystrophy (DMD). It aims to correct the faulty instructions at the DNA level, straightforward, at least conceptually, because mutations are deletions, of part or all of the gene. That’s not the case for ALS.

Therapies 81

Therapies FDA Clinical Trials DNA 81

Codon

MARCH 26, 2023

Link A DNA tumor virus globally reprograms host 3D genome architecture to achieve immortal growth. Link DNA storage in thermoresponsive microcapsules for repeated random multiplexed data access. Link Semi-rational evolution of a recombinant DNA polymerase for modified nucleotide incorporation efficiency. Nucleic Acids Research.

DNA 52

DNA Engineering RNA Small Molecule 52

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Malaria mortality from 2000 (left) to 2019 (right).

Vaccine 52

Vaccine DNA Virus Engineering 52

Codon

APRIL 23, 2023

Unfortunately, they can also trigger immune responses, and they are not super efficient at gene-editing some parts of the brain. These ribonucleoproteins also caused a lower immune response compared to the viruses, and are much easier to make in the lab. Malaria mortality from 2000 (left) to 2019 (right).

Vaccine 52

Vaccine DNA Virus Engineering 52